Mereo BioPharma Group plc Stock London S.E.
Equities
MPH
GB00BZ4G2K23
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- GBX | -.--% | -10.17% | -.--% |
Sales 2024 * | 27.5M 34.43M 47.08M | Sales 2025 * | 12.5M 15.65M 21.4M | Capitalization | 339M 425M 580M |
---|---|---|---|---|---|
Net income 2024 * | -8M -10.02M -13.7M | Net income 2025 * | -28M -35.06M -47.93M | EV / Sales 2024 * | 7.66 x |
Net cash position 2024 * | 128M 161M 220M | Net cash position 2025 * | 142M 178M 243M | EV / Sales 2025 * | 15.8 x |
P/E ratio 2024 * |
-323
x | P/E ratio 2025 * |
-65.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 46.94% |
Managers | Title | Age | Since |
---|---|---|---|
John P. Richard
FOU | Founder | 66 | 15-02-28 |
Founder | 64 | 15-07-09 | |
Charles Sermon
FOU | Founder | 55 | 15-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 19-04-22 |
Director/Board Member | - | 22-11-09 | |
Director/Board Member | 59 | 19-04-22 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- MREO Stock
- MPH Stock